Johnson & Johnson vs Gilead Sciences, Inc.
A head-to-head of Johnson & Johnson (JNJ) and Gilead Sciences, Inc. (GILD) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | JNJ | GILD |
|---|---|---|
| Market Cap | $555.94B | $160.15B |
| P/E (TTM) | 25.81 | 17.57 |
| Forward P/E | 17.72 | 14.02 |
| P/S | 5.77 | 5.61 |
| P/B | 8.58 | 6.84 |
| EV/EBITDA | 17.48 | 12.15 |
| Dividend Yield | 1.80% | 2.52% |
| Profit Margin | 21.83% | 30.99% |
| Gross Margin | 67.88% | 78.83% |
| Operating Margin | 27.17% | 39.74% |
| Revenue Growth (YoY) | +9.91% | +4.39% |
| FCF Yield | 3.13% | 6.13% |
| Debt / Equity | 67.73 | 94.64 |
| Current Ratio | 1.03 | 1.97 |
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.